GSK Confirms Arexvy Price And US Contract Negotiations Ahead Of Launch
Talks Crucial To Launch Success
GSK is gearing up for its most important new product launch in years and hopes US payers will buy into Arexvy’s likely higher price than Pfizer’s rival RSV vaccine.
